Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07212465

Accelerated Neuromodulation of Anterior Cingulate Cortex for Depression

The goal of this clinical trial is to test whether an accelerated deep Transcranial Magnetic Stimulation (dTMS) protocol can reduce depressive symptoms in older adults (ages 60-85) with Major Depressive Disorder (MDD) who have not tolerated or responded to antidepressant medications. The study will evaluate whether accelerated dTMS administered over 5 consecutive days is safe and well-tolerated in this population, and whether it produces greater reductions in depressive symptoms compared to placebo stimulation.

Recruiting

Interested in participating?

Request Info

Key information

Age range

60 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rotman Research Institute at Baycrest

Toronto, Ontario, M6A 2E1, Canada

Location status: Recruiting

Location contact

Linda Mah, MD

CONTACT

[email protected]

416-785-2500 ext. 3434

About this study

This study will investigate the effects of an accelerated intermittent theta burst protocol (a-iTBS) using the H7 deep Transcranial Magnetic Stimulation (dTMS) coil to target the anterior cingulate cortex (ACC) in older adults (aged 60-85) with Major Depressive Disorder (MDD). Twenty-four older adults with treatment-resistant MDD will participate in a single site, double-blind, randomized sham-controlled trial using an accelerated schedule of multiple dTMS sessions per day for 5 consecutive days. The primary goal of the study is to establish the feasibility of an accelerated aiTBS protocol of the ACC in older adults with treatment resistant depression, and to obtain preliminary evidence of treatment efficacy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • are between 60- 85 years old (on the day of randomization)
  • have been diagnosed with DSM5 Major Depressive Disorder, with the current episode longer than 4 weeks but less than 5 years
  • did not respond to/did not tolerate, or failed to achieve remission with at least one antidepressant trial of 8 week minimum duration
  • are willing to provide informed consent
  • are able to follow the treatment schedule
  • are stable on medications for 2 months and are not expected to change medication during the entire study period (if they are taking medications)
  • have a satisfactory safety screening questionnaire for TMS

Exclusion criteria

  • have a metal plate in your head (such as an ear implant, implanted brain stimulators, aneurysm clips). Dental devices and implants that are non-magnetic are safe
  • have known increased pressure or a history of increased pressure in their brain, which may increase their risk for having seizures
  • have a cardiac pacemaker
  • have an implanted medication pump
  • have a central venous line
  • have a history of any psychotic disorder, bipolar disorder, eating disorder, obsessive compulsive disorder, post-traumatic stress disorder, or dementia
  • have a history of substance abuse in the last 6 months
  • have a history of stroke or other brain lesions
  • have a personal history of epilepsy
  • have a family history of epilepsy
  • are a pregnant or breast-feeding woman
  • have a history of abnormal MRI of the brain
  • have untreated hypo- or hyper-thyroidism
  • have unstable medical condition(s)
  • have any other known contraindications to TMS
  • are on unstable doses of any psychotropic medication such as - antidepressants, antipsychotic, mood stabilizers or memory enhancing medications
  • require daily doses of benzodiazepines or hypnotics within two weeks of randomization

Treatment and study plan

Active Brainsway H7-Coil Deep TMS System

Device

Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel dTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions. dTMS will be administered 6-8 times a day for 5 consecutive days.

Sham Brainsway H1-Coil Deep TMS System

Device

In addition to the active H7-coil, a sham coil is included in the H1-coil helmet. The sham treatment will be administered 6-8 times a day for 5 consecutive days.

Primary outcomes

  1. Percentage of scheduled treatment sessions that are attended by study participants

    Time frame: 6 weeks

  2. Participant-reported comfort and feasibility based on the frequency and type of adverse events as measured using the Adverse Events Questionnaire (AEQ)

    Time frame: 6 weeks

    Severity of symptoms is rated from 1 to 4, with 1 being absent and 4 being severe. Whether symptoms are perceived to be relatedTMS treatment are rated from 1 to 5, with 1 being no and 5 being definitely.

  3. The number of participants who have prematurely withdraw and reasons for withdrawal

    Time frame: 6 weeks

  4. The change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) scores following the final treatment on day 5 (i.e., after 5 days of H7-coil a-iTBS) in the treatment group compared to the sham group.

    Time frame: 1 week

    An effect size (Cohen's d) of 0.5 will be considered a minimally important effective size. The MADRS ranges from 0-60, with a greater score indicating greater depressive symptoms.

Secondary outcomes

  1. Response rates compared between treatment groups following 5 days of treatment, where the response rate refers to the percentage of patients who responded to a-ITBS treatment and response is defined as a ≥50% reduction in MADRS score from baseline

    Time frame: 6 weeks

    Response rates will be compared from baseline to after 5 day treatment and at 1 month follow-up. MADRS scores range from 0-60, with a greater score indicating greater severity of depressive symptoms.

  2. Remission rates compared between treatment groups following 5 days of treatment, where the remission rate is defined as MADRS score <10

    Time frame: 6 weeks

    MADRS scores will be compared between baseline, after 5 days of treatment and at 1-month follow-up. The MADRS ranges from 0-60, with a greater score indicating greater depressive symptoms

  3. The change in baseline slow wave and resting state activity as measured with electroencephalography (EEG) following 5 days of treatment and at 1-month follow-up

    Time frame: 6 weeks

  4. The change in functional connectivity within the default mode and central autonomic networks on Magnetic Resonance Imaging (MRI)

    Time frame: 1 week

  5. The change in slow wave activity in the posterior default mode network (posterior cingulate cortex) as measured with MEG

    Time frame: 1 week

  6. The change in baseline cognitive tests following 5 days of treatment and at 1-month follow-up (cognitive domains tested include executive function and memory),

    Time frame: 6 weeks

    Baseline cognitive tests will be measured using a neuropsychological test battery.

  7. The change in baseline resting state heart rate variability (HRV) following a single TMS session and after 5 days of treatment

    Time frame: 1 week

  8. The change in baseline emotional processing as measured with an Affective Simon task following a single TMS session, after 5 days of treatment and at 1-month follow-up

    Time frame: 6 weeks

    The Affective Simon task will measure the number of correct responses to stimuli in the task.

Study contacts

Contact information is provided by the study sponsor or research team.

Amanda Chao, MPH

CONTACT

[email protected]

416-785-2500 ext. 3434

Linda Mah, MD

CONTACT

[email protected]

416-785-2500 ext. 3434

Sponsors and collaborators

Lead sponsor

Rotman Research Institute at Baycrest

Other

Registry information

Official study title

Feasibility, Tolerability, and Preliminary Efficacy for Non-Invasive Neuromodulation of the Anterior Cingulate Cortex for Depression (NACC-D) in Older Adults Using Deep Transcranial Magnetic Stimulation With an Accelerated Intermittent Theta Burst Protocol

Acronym: NACC-D

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Oct 8, 2025
Registry last updated
Oct 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.